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Low-income  countries  typically  lag  behind  industrialised  nations,  where  the  introduction  of  new  vaccines
is  commonly  tailored  to the pressures  of  the  commercial  market.  Happily  in  recent  years  this  paradigm
has started  to change  with  the  introduction  of  a univalent  meningococcal  A conjugate  vaccine  that  is
speciﬁcally  targeted  for  the  prevention  of epidemic  meningitis  in  Africa.  The  declaration  of  the  2010s  as  aonjugate vaccines
djuvants
everse vaccinology
MMA
enomics
New  Decade  of  Vaccines,  together  with  Millennium  Development  Goals  4  and  5, provide  a  strong  mandate
for  a  new  approach  to  the  development  of  vaccines  for  low-income  countries,  so that  there has  never
been a more  exciting  time  to  work  in  this  ﬁeld.  This  review  considers  the  opportunities  and  challenges  of
developing  these  new  vaccines  in  the  context  of  innovations  in vaccinology,  the  need  to  induce  protective
immunity in  the  populations  at risk  and  the  requirement  for strong  partnership  between  the  countries
that will  use  these  vaccines  and  different  elements  of  the  vaccine  industry.
 201. Introduction
Vaccination has had an unrivalled impact on global health [1]
nd vaccines have the greatest potential for further improvement
n health in the poorest countries of the world. Infectious diseases
ccount for around half of all deaths in these countries with around
0% of this mortality being attributed to diarrhoeal and respiratory
iseases, AIDS, tuberculosis, malaria and measles [2]. In addition
o the direct beneﬁt of vaccines in preventing disease and death,
here is growing evidence that their widespread implementation
eads to much-needed economic development [3,4].
Vaccination is very much on the global agenda and underpins
wo of the United Nations’ Millennium Development Goals: the
eduction of child mortality (Goal 4) and improvement of mater-
al health (Goal 5) [5]. The establishment of the Global Alliance for
accines and Immunizations (GAVI) at the World Economic Forum
n Davos, Switzerland, in 2000 has been key to the deployment of
accines in low income countries. This public–private partnership
as a mission to save children’s lives and improve global health
y increasing access to vaccines in low-income countries [6]. Ten
ears later, again at the World Economic Forum in Davos, the Bill
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support the research, development and delivery of vaccines for the
poorest countries in a New Decade of Vaccines [7].
Despite the acknowledged importance of vaccines for low-
income countries, there are major challenges to their effective
implementation and the realisation of the enormous potential ben-
eﬁts of vaccines. This review will discuss the opportunities for
developing and implementing vaccines for low-income countries.
The challenges this poses will be considered along with the poten-
tial for exploiting new technologies and innovations in this ﬁeld of
vaccinology.
2. The Expanded Programme on Immunisation
The greatest beneﬁt to date from the use of vaccines in
low-income countries has been achieved through the Expanded
Programme on Immunisation (EPI). This was  introduced in 1974
by World Health Assembly resolution WHA27.57 to build on the
success of smallpox eradication by making vaccines available to
children in all countries [8]. Vaccines to prevent diphtheria, tetanus,
pertussis, measles, poliomyelitis and tuberculosis were the ﬁrst to
be introduced into the EPI, with the aim of immunising children
at between two  and six months of age. By 2009, with the support
of GAVI, now renamed the GAVI Alliance, 82% of infants world-
wide had received three doses of diphtheria, tetanus and pertussis
3 The Author. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.vaccine through the EPI [9].
More recently, the EPI has been used to deliver vaccines to pre-
vent infection with hepatitis B virus (HBV), Haemophilus inﬂuenzae
b (Hib), Streptococcus pneumoniae and rotavirus. The high coverage
icense.
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ate of the programme makes it an attractive platform for the deliv-
ry of new childhood vaccinations to low-income countries. There
re problems associated with this. The crowding of the EPI schedule
ith more vaccines involving more injections and the possibil-
ty of immunological interference threatens to diminish vaccine
ffectiveness. Also, the immaturity of immune system at the young
ge when EPI vaccines are administered can result in sub-optimal
esponses compared to those of older children. This may  necessitate
ultiple doses of vaccine in the primary vaccination schedule and
ooster doses when children are older. Finally, maternal antibody
ransferred to the infant transplacentally or through breast-feeding
an potentially impair the response to vaccines given in the EPI
chedule. This particularly applies to live attenuated viral vaccines
uch as the measles vaccine [10].
. Requirements of new vaccines for low-income countries
Several factors are important when considering the suitability of
ew vaccines for low-income countries. The vaccine itself needs to
e safe and immunogenic. It needs to induce an immune response
n the target population that provides broad protective coverage
gainst the prevalent strains of the pathogen targeted by the vac-
ine and new strains that might emerge following the introduction
f the vaccine. Ideally the vaccine will induce life-long immunity
ollowing one dose without the need for subsequent boosting. It
hould also be thermostable and amenable to needle-free deliv-
ry. The results from clinical trials of new vaccines in industrialised
ountries do not necessarily predict the responses that will be
licited or the protection afforded by the same vaccines in low-
ncome countries. This is well recognised for the live oral vaccines
ncluding those against polio [11], rotavirus [12] and cholera [13]. It
ay  be due to a number of reasons including chronic environmen-
al enteropathy, malnutrition, maternal antibodies and host genetic
actors [14].
Co-infections, particularly with HIV, can have a major impact
n the immune response to a vaccine and its clinical effective-
ess. A dramatic example of this was in a clinical trial of 23-valent
olysaccharide pneumococcal vaccine among HIV-infected adults
n Uganda. The trial found no protection against invasive pneumo-
occal disease (including disease caused by serotypes included in
he vaccine) and a higher rate of all-cause pneumonia in vaccinees
ompared with the control arm [15]. Reduced vaccine effectiveness
t preventing disease can also result from differences in disease-
ausing serotypes and prevalent strains in low-income countries
ompared to high-income countries. This problem is well exempli-
ed by the relatively low coverage of the 7-valent pneumococcal
onjugate vaccine in Africa [16].
Affordability is key for the introduction of new vaccines into
ow-income countries. Development of new vaccines is a time-
onsuming and costly process involving several steps. Many of the
ewer vaccines that have been or are being developed primarily for
ndustrialised markets are considerably more complex than the tra-
itional empirical vaccines. Their multiple components drive up the
asic cost-of-goods of the vaccine. The clinical trials required dur-
ng vaccine development, especially Phase 3 clinical efﬁcacy trials
hat involve thousands of participants, are particularly expensive.
herefore, it is important to seek to use simpliﬁed and affordable
echnologies and innovations that minimise the cost of develop-
ent and the ongoing production costs of new vaccines to be used
n low-income countries.
Vaccines for low-income countries must be seen to address alear public health need in the target countries and represent a
lear beneﬁt for the cost incurred by their implementation. In order
or this to happen, involvement of the developing countries in the
accine development process is essential with early interactionunology 25 (2013) 114– 123 115
between vaccine companies, the public, healthcare professionals
and local as well as global health policy decision makers (Section
9).
4. Introduction of vaccines developed for high-income
countries into low-income countries
New vaccines for which there is a need in high-income, as
well as low-income countries, present a more attractive com-
mercial incentive to the pharmaceutical industry than vaccines
that will only be used in low-income countries. A recognised
need in high-income countries led to the development of the
ﬁrst Hib polysaccharide–protein conjugate vaccines in the 1980s
and pneumococcal polysaccharide–protein conjugate vaccines in
the 2000s for the prevention of lower-respiratory tract diseases.
Although of clear usefulness for low-income countries, where
lower-respiratory tract diseases have been the commonest cause
of childhood mortality, there were delays of between 10 and
20 years between the ﬁrst use these vaccines in industrialised
countries and their introduction into low-income countries [17].
It is important to strive to prevent similar disparities in the
introduction of new vaccines. More recently, the Rotarix vaccine
(GlaxoSmithKline) against rotavirus, an infection that is respon-
sible for diarrhoeal diseases in high- and low-income countries,
was  released simultaneously in Latin America and high income
countries [18].
A number of reasons can underlie the delay in the use of vac-
cines in low-income countries including the necessary ﬁnancing
for their implementation and the clear recognition of their pub-
lic health beneﬁts. These problems have been addressed by a new
strategy of ﬁnancing through the GAVI Alliance known as Advanced
Market Commitments [19], together with accelerated development
and introduction plans for pneumococcal and rotavirus vaccines in
2003, and Hib vaccine in 2005 which ﬁlled information gaps on
these vaccines [17]. While Hib conjugate vaccines are monovalent,
pneumococcal conjugate vaccines are polyvalent and consequently
are an example of a modern complex vaccine with higher associ-
ated cost-of-goods. The initial 7-valent pneumococcal conjugate
vaccine was  replaced with a 13-valent vaccine including the three
commonest pneumococcal serotypes causing disease in Africa.
Nevertheless, there is ongoing evidence of replacement of disease-
causing serotypes following vaccine introduction [20]. This has led
to attempts to develop protein-based vaccines against pneumococ-
cus [21].
5. Development of vaccines only needed in low-income
countries
Development of new vaccines that are only required in low-
income countries present a major challenge due to the absence of
a clear commercial return to the vaccine manufacturer. Despite
this, a new monovalent conjugate vaccine against meningococ-
cus serogroup A was  developed in the 2000s [22] speciﬁcally for
use in the African Meningitis Belt where this serogroup has been
responsible for the majority of meningitis epidemics. The vac-
cine, MenAfriVac, came from a new global health partnership, the
Meningitis Vaccine Project [23]. This is a joint effort between the
Programme for Appropriate Technology in Health (PATH) and the
WHO, with ﬁnancial support from the BMGF. The vaccine is priced
at less than US$1 per dose. Mass immunisation campaigns began
with the new vaccine in 2010 in Burkina Faso, Mali and Niger,
and the vaccine is subsequently being rolled out across the entire
African Meningitis Belt.
By developing a new low-cost vaccine that, from the outset,
was  speciﬁcally targeted at low-income countries, the Meningitis
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accine Project has established a new paradigm in vaccine devel-
pment. This involved the transfer of necessary conjugate vaccine
echnology to the Serum Institute of India Ltd., a manufacturer
f low-cost vaccines. Similar technology transfers will be key for
trengthening emerging manufacturers and should lead to sustain-
ble low-price vaccine production [19]. In one year, meningococcal
 disease was essentially eliminated from Burkina Faso [24]. This
as accompanied by a herd immunity effect with the disappear-
nce in carriage of meningococcus A among both vaccinated and
nvaccinated individuals [25]. Nevertheless, continuing outbreaks
f meningitis due to other meningococcal serogroups, particular
erogroups W and X, have underlined the need for a second-
eneration vaccine with broader coverage against meningococcus.
. New vaccines still required for low-income countries
The development of vaccines against malaria and HIV, and new
accines against tuberculosis, still represent major challenges for
lobal health vaccinology. These challenges are being approached
ith a high level of cooperation between public and private sectors
orking through the PATH Malaria Vaccine Initiative (MVI) [26],
lobal HIV Vaccine Enterprise [27] and Aeras tuberculosis initiative
28]. A key immunological problem presented by malaria and HIV
s the high degree of antigenic diversity for both pathogens, com-
ounded by the high rate of mutation of the HIV RNA virus and the
ultiple stages of infection of Plasmodium falciparum.  Supported
y the MVI, and with considerable funding from the BMGF, Glax-
SmithKline’s sporozoite antigen-based RTS,S/AS01 vaccine gave
6% efﬁcacy against clinical malaria in a multicentre Phase 3 clin-
cal trial in Africa [29]. Disappointingly, clinical efﬁcacy dropped
o 30% when RTS,S/AS01 was co-administered with EPI vaccines to
frican infants aged 6–12 weeks [30].
HIV vaccines are much less advanced, though the identiﬁcation
nd improved understanding of broadly-neutralising antibodies
gainst the virus could help rational design of new vaccine can-
idates [31]. BCG (bacillus Calmette-Guérin) has been used to
accinate against tuberculosis for almost a century, but provides
imited protection, particularly in low-income countries, where,
ogether with the HIV/AIDS pandemic, tuberculosis has become an
ncreasing problem. Efforts have been targeted at improving the
CG vaccine and the immune response it induces [32]. The develop-
ent of new and improved vaccines against tuberculosis continues
o be a global health priority.
The diarrhoeal diseases have long been the major group of
eglected infectious diseases in low-income countries, only rivalled
y lower respiratory tract disease in their contribution to mortality
n children under ﬁve years of age. With the increasing implementa-
ion of pneumococcal and Hib vaccination in low-income countries,
he prominence of the diarrhoeal diseases on the global health
genda will increase. Unlike respiratory diseases, diarrhoeal dis-
ases, with the exception of rotavirus, have lacked the commercial
ncentive of a large industrialised market [33]. Progress towards
accine development has also been hampered by an incomplete
nderstanding of the aetiology and epidemiology of diarrhoea in
ow-income countries.
Both of these obstacles are being addressed with the emergence
f new institutes speciﬁcally established to develop vaccines for
ow-income countries (Section 7) and through improved under-
tanding of the aetiology of diarrhoea through the BMGF-supported
lobal Enterics Multicenter Study (GEMS) [34]. Recently, much
ffort has gone into developing new conjugate vaccines against
yphoid fever based on the Vi capsular antigen of Salmonella Typhi
35], some 10 years after the clinical proof of concept was  estab-
ished for such vaccines [36]. The existing Vi polysaccharide and
y21a live attenuated vaccines against typhoid have not beenunology 25 (2013) 114– 123
widely implemented in low-income countries for various rea-
sons including lack of suitability for use in young children [35].
New vaccines are in development against a number of other diar-
rhogenic infections including paratyphoid fever [37], nontyphoidal
Salmonella [38], Shigella [39] and cholera [40].
Vaccines against pneumonia and meningitis have already been
discussed together with the need to cover strains prevalent in
low-income countries, while maintaining affordability. Neisseria
meningitidis serogroup X emerged in Africa in 2006 as a new
serogroup capable of causing epidemic meningococcal meningitis
[41]. A vaccine that protects against this serogroup is still required.
There is little demand for vaccines in high-income countries against
the parasitic diseases included in the WHO  list of ‘neglected trop-
ical diseases’. Effective vaccines against these infections would
have a major impact on health in low-income countries [42]. No
vaccine against these diseases has yet been licenced and the devel-
opment of such vaccines is faced with a number of technically
difﬁculties. For many of the parasitic diseases, affordable effective
medicines are available [43] which may  serve as a disincentive for
vaccine development. Other infections that affect low-income, but
not high-income countries, for which there is a demand for vac-
cines, include dengue and Japanese encephalitis. There is still a
need to combat other infections, including Group A and B Strep-
tococcus and Staphylococcus aureus in both high- and low-income
countries. While Group A Streptococcus causes pharyngitis and oti-
tis media in high-income countries, it has a devastating effect on
health in low-income countries as the causative agent of rheumatic
heart disease. A vaccine approach to ameliorating these infections
should continue to be a target for research and development.
7. Global vaccine institutes and initiatives
MVI, the Global HIV Vaccine Enterprise and the Aereas tuber-
culosis initiative have drawn together coordinated support for the
development of vaccines against these ‘big three’ diseases affecting
low-income countries. Despite these important initiatives, there
is a need to drive the development of vaccines against other dis-
ease affecting low-income countries, particularly those for which
there is no high-income country market and commercial incentive.
This need has partly been addressed by establishing of a number of
institutes focused on vaccines for low-income countries.
The Sabin Vaccine Institute in Washington, DC,  USA, is the oldest
of these [44]. It was founded in 1993 as a not-for-proﬁt organisation
to deal with potentially-vaccine-preventable neglected tropical
diseases. The institute is working on vaccines against hookworm,
schistosomiasis and malaria. The International Vaccine Institute
(IVI) in Seoul, Republic of Korea, was established in 1997 with a
focus on infectious diseases in Asia [45]. This has gone a long way to
furthering our understanding of the epidemiology of these diseases
and has been involved in developing vaccines against Japanese
encephalitis, Shigella, cholera and Salmonella Typhi.
In 2007, the Novartis Vaccines Institute for Global Health
(NVGH) was  created by the Novartis Foundation with a public
health mission to develop vaccines against diseases of impover-
ished communities in low-income countries [46,47]. NVGH was  the
ﬁrst industry-linked vaccine institute. It has the advantage of access
to technologies and skills of a major vaccine manufacturer, being
co-located with the main research centre of Novartis Vaccines and
Diagnostics in Siena, Italy. To date, it has developed a polysac-
charide conjugate vaccine against typhoid fever (Vi-CRM197) [48]
which has been tested in Phase 2 clinical trials in South-East Asia,
and has vaccines against Salmonella Paratyphi A, invasive non-
typhoidal Salmonella disease (iNTS), Shigella and meningococcal
meningitis in Africa in preclinical development. More recently,
the pharmaceutical company, Merck, in partnership with the
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ellcome Trust, founded the Hilleman Laboratories in India with a
imilar mission to develop vaccines for low-income countries [49].
Academic institutions perform early-stage research that can
ead to new vaccines, but it is the institutes described above that
ave the infrastructure and access to the expertise required to
ndertake the technical development required to see a vaccine
oncept move from research through to clinical trials. Even these
lobal vaccine institutes are unlikely to have the resources required
o undertake randomised controlled Phase 3 clinical trials. For-
unately there are a growing number of vaccine companies in
ountries including India, China and Brazil, such as the Serum Insti-
ute of India, that have the capacity for developing new vaccines.
ince the global vaccine institutes are relatively small compared
o commercial vaccine companies, good levels of collaboration
etween these two industrial sector partners, and with developing
orld and academic partners will be key to the successful develop-
ent and deployment of new vaccines for low-income countries
Section 9). This is likely to require a level of openness and com-
unication that is currently uncommon in the pharmaceutical
ndustry.
. Technologies and innovations for vaccines for
ow-income countries
.1. Vaccine technologies
Many of the technologies and innovations leading to the devel-
pment of current and future novel commercial vaccines for
igh-income countries can be adopted for low-income country vac-
ines provided the cost of the ﬁnal products is not prohibitive. Other
echnologies are being developed with the speciﬁc goal of produc-
ng effective, affordable and safe vaccines for low-income countries.
mportantly, these technologies may, in due course, be useful for
he development of vaccines for high-income countries. This could
everse the current paradigm of technology ﬂow from high-income
ountry to low-income country vaccine development.
.1.1. Conjugation
Conjugation of polysaccharide antigen to protein carrier has
een effectively used in the development of the MenAfriVac
accine, with meningococcal group A capsular polysaccharide
ovalently linked to tetanus toxoid (Fig. 1) [22]. Although long-
erm efﬁcacy of this vaccine in the African Meningitis Belt is yet
o be established, the early results have been impressive. Follow-
ng its introduction in Burkina Faso, no cases of meningococcal
roup A disease were detected in 2012 [24]. This vaccine has super-
eded pure polysaccharide vaccines which were used previously to
ontrol of serogroup A meningitis outbreaks [50].
Conjugate vaccines effectively convert T-independent antigens
nto T-dependent antigen, imparting the capacity for producing
ersistent high-afﬁnity antibody production and immunological
emory. This is achieved by linking a carrier protein to the polysac-
haride antigen (Fig. 1). In this way, B cells speciﬁc for the capsular
olysaccharide antigen obtain help from T cells responsive to
eptides of the linked protein [51]. In comparison to conjugate
accines, pure polysaccharide vaccines have several disadvan-
ages. They fail to evoke immunological memory or long-lived
ntibody production. Consequently, long-lasting protection is not
onferred and there is evidence of hyporesponsiveness to sub-
equent vaccination with the same pure polysaccharide antigen
52,53]. Afﬁnity maturation of the antibody response does not
ccur in responses to pure polysaccharides, so the efﬁciency of the
ntibody induced is often lower that that induced by conjugate vac-
ines. The immature immune system of young children responds
oorly to pure polysaccharide antigens. Consequently protectionunology 25 (2013) 114– 123 117
afforded by these vaccines is not available in this age group which
is naturally susceptible to encapsulated bacteria. Finally, unlike
meningococcal conjugate vaccines, there is no evidence that pure
polysaccharide vaccines can reduce carriage or impact on transmis-
sion of meningococci. As mentioned earlier, conjugate technology
has been applied to the development of new vaccines against
typhoid and paratyphoid fever for use in low-income countries
[37,54].
8.1.2. New adjuvants
Adjuvants are used in licenced low-income country vaccines and
those in development. In addition to alum, newer adjuvants include
MF59 [55,56], AS01 [29], improved alum formulations and spe-
ciﬁc TLR-agonists [57]. These convey similar advantages to those
for high-income country vaccines, although the advantages are
potentially more beneﬁcial in the developing world setting. It is
recognised that in low-income country populations vaccines may
induce inadequate immune responses and immunity wane more
rapidly than in high-income country populations (Section 3). New
and more effective adjuvants could minimise these effects, trans-
forming suboptimal vaccine candidates into effective vaccines.
There is a particular need to achieve such an improvement in the
current BCG vaccine for tuberculosis [32] and new vaccines against
malaria.
From a pragmatic perspective, effective adjuvants can reduce
the cost of vaccines, a key consideration for low-income countries.
This is partly achieved by reducing the quantity of vaccine antigen
required per dose, but more signiﬁcantly, by reducing the number
of doses required in a vaccination schedule and reducing the need
for booster doses in the future. A further practical advantage is that
the number of clinic visits required by each child is reduced. This
is likely to increase the uptake of the vaccine, the proportion of the
population with protective immunity and the chance of producing
a herd-immunity effect.
8.1.3. Reverse vaccinology
Reverse vaccinology was ﬁrst applied to the development of a
vaccine against group B meningococcus [58]. A capsular polysac-
charide conjugate vaccine was  not feasible for this serogroup
of meningococcus due to cross-reactivity with human antigens.
Reverse vaccinology uses the genome of a pathogen to determine
the repertoire of potential antigens for that organism. These anti-
gens are then cloned and expressed in Escherichia coli,  puriﬁed and
used to vaccinate experimental animals to determine their poten-
tial to induce protective immunity [59]. The key meningococcal
antigen discovered through the reverse vaccinology approach was
factor H binding protein (fHbp), previously known as lipoprotein
GNA1870 [60] and N. meningitidis 2086 lipoprotein [61], which is
expressed by invasive meningococci from all serogroups. With the
knowledge that fHbp is also expressed by invasive meningococcal
strains from the African Meningitis Belt [62], fHbp is being incorpo-
rated into new broadly-protective vaccines for use in low-income
countries [62,63].
The identiﬁcation of key protective antigens that are conserved
across a broad range of strains of a particular pathogen has good
potential for the development of simpler affordable vaccines and
counteracts the need for vaccines with increasing valencies, such as
the current pneumococcal conjugate vaccines. Reverse vaccinology
is being applied to the development of vaccines against a number of
other pathogens including Group A [64] and Group B Streptococcus
[65], and pathogenic forms of E. coli [66]. These could have great
potential to improve health in both low and high-income countries.8.1.4. Generalised Modules for Membrane Antigens (GMMA)
A new technology that has been developed with a focus on
vaccines for local-income countries is GMMA [67]. It is well
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Fig. 1. Conjugate vaccine technology used in meningococcal A vaccine for African Meningitis Belt. (A) The ﬁrst vaccines used to combat meningococcal meningitis in Africa
consisted of pure polysaccharide from meningococcus serogroups A and C. These stimulate speciﬁc B cells to induce antibody production. However, they are T-independent
type  2 antigens and have a number of disadvantages. There is no afﬁnity maturation of the antibody response, class switching is limited, immunological memory is not produced
and  there can be hyporesponsiveness to subsequent vaccination. Such vaccines generate poor responses in young children and have no effect on pathogen transmission. (B)
Conjugation of tetanus toxoid to meningococcal A polysaccharide has been used in the newly-implemented meningococcal A conjugate vaccine in the African Meningitis
Belt.  This effectively converts the T-independent polysaccharide antigen into a T-dependent antigen by enlisting T cell help through the internalisation of the protein moiety,
followed by processing and presentation of peptides on MHC  class II molecules which are recognised by T cell receptors on speciﬁc CD4+ T cells. The consequences of this
are  improved vaccine function with afﬁnity maturation leading to high afﬁnity antibody production, increased class-switching and induction of memory with boosting
on  subsequent vaccination. There are improved responses in young children compared with pure polysaccharide vaccines and reduced pathogen carriage leading to herd
immunity. Men  A PS – meningococcal A polysaccharide; TCR – T cell receptor.
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Fig. 2. GMMA technology for affordable, immunogenic and broadly-protective
low-income country vaccines. Spontaneous blebbing of the outer membrane of
Gram-negative bacteria occurs naturally at low levels. This process can be manipu-
lated by disruption of the Tol-Pal system which is responsible for maintaining the
integrity of the inner and outer membranes of the bacteria, leading to a large increase
in  the production of these blebs known as GMMA  (Generalised Modules for Mem-
brane Antigens). GMMA  are essentially enriched forms of bacterial outer membrane
and outer membrane components containing periplasm, but lacking inner mem-
b
r
l
r
b
p
s
crane and cytoplasmic components which are rarely targets of protective antibody
esponses. GMMA  are easily puriﬁed, highly immunogenic and can be produced at
ow cost.
ecognised that Gram-negative bacteria spontaneously release
leb-like particles of outer cell wall membrane (Fig. 2) [68]. The
urpose of these blebs is unclear, but they constitute an enriched
ource of outer membrane-associated antigens in their native
onformation and orientation. The integrity and attachment ofunology 25 (2013) 114– 123 119
the inner and outer bacterial cell wall membranes is normally
maintained by the Tol-Pal system. Disruption of the Tol-Pal sys-
tem increases the rate of GMMA  production enabling exploitation
of these particles as vaccines (Fig. 2). For many Gram-negative
bacteria, including Salmonella,  Shigella and E. coli, Tol-Pal sys-
tem disruption can be achieved through deletion of the tolR gene
[67], while for meningococcus, GMMA  release can be increased
by deleting gna33 [69]. GMMA  differ from Outer Membrane Vesi-
cles (OMV) extracted from whole bacteria using detergent which
causes the loss of a number of outer membrane components includ-
ing lipoproteins such as fHbp. This results in OMV  having reduced
immunogenicity compared with GMMA.  Meningococcal serogroup
B OMV  were used to halt an epidemic of meningococcal group
B disease in New Zealand [70] and the success of the vaccina-
tion campaign relates to the homogeneity of the strains involved.
Through the loss of key antigens, OMV  have limited effectiveness in
protecting against other meningococcal group B strains and other
meningococcal serogroups.
GMMA  are currently being explored as vaccines for meningo-
coccus [71], Shigella [67] and Salmonella.  The expression of complex
outer membrane proteins in their native conﬁrmation and correct
orientation in GMMA,  provides signiﬁcant potential advantages
over recombinant proteins. Unlike whole bacterial vaccines, GMMA
lack inner membrane and cytoplasmic components which are
rarely the targets of protective immunity. GMMA also contain
pathogen associated molecular patterns (PAMPs), including TLR
ligands, which have the potential to act as self-adjuvants in the
immune responses they elicit. There is a need to detoxify the
lipopolysaccharide or lipooligosaccharide present in GMMA  and
this is usually done through the introduction of a further mutation,
for example in the lpxL1 gene of meningococcus [72]. A prototype
meningococcal GMMA  has been tested in one Phase 1 clinical trial
without adverse effects [73] and preclinical animal studies with
new GMMA  candidate vaccines indicate good immunogenicity and
broad cross protective immunity against a variety of strains [63].
8.2. Innovation in vaccine production
In addition to the available and emerging vaccine technologies,
innovation in vaccine production methods can beneﬁt the devel-
opment of vaccines for low-income countries. These innovations
ideally serve to make vaccine production simpler, more cost effec-
tive and safer. The new GMMA  class of vaccine lend themselves to
simple production methods, since they are spontaneously released
by appropriate vaccine bacterial seed strains. A low cost method of
GMMA  puriﬁcation has been developed recently using tangential
ﬂow ﬁltration with minimal need for further downstream process-
ing [67]. Consequently, this technology may  allow new vaccines
for low-income countries to be manufactured by the countries
that need them. Technologies that are both simple, and safe will
help establish new vaccine industries in the developing world.
Two innovations in the development of the Vi-CRM197 typhoid
vaccine and O:2-CRM197 vaccine component against Salmonella
Paratyphi A by NVGH have improved the safety of the vaccine pro-
duction process. Instead of fermenting Salmonella Typhi, a human
pathogen which requires containment in BSL3 facilities, Vi polysac-
charide is obtained from a Vi-expressing strain of Citrobacter
which requires no special containment conditions [74]. O-antigen-
containing lipopolysaccharide is normally extracted from bacteria
using a hot phenol method which is potentially hazardous as well
as expensive. A method has been optimised that enables the direct
harvesting of O-antigen from whole S. Paratyphi A bacterial cultures
using acid hydrolysis and involves boiling the bacteria in dilute
acetic acid [37].
The time for a new vaccine to move from inception to clini-
cal use often takes ten or more years. Steps that reduce this time
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ers in low-income countries (Fig. 3). Without early and ongoing
engagement between these two  sides, current efforts could results
in sub-optimally designed vaccines or vaccines that will not be
implemented.
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or new low-income country vaccines could result in thousands of
ives saved and so innovations in the vaccine development pathway
ould have great potential value. There are two major bottlenecks in
his pathway. The ﬁrst is access to the technical development capac-
ty required for the manufacture of GMP  lots of candidate vaccines.
he second is the time taken to obtain ﬁnal approval by the regula-
ory authorities prior to licensure. Technical development capacity
an be a limiting factor for the commercial vaccine industry as well
s global vaccine institutes.
Streamlining of the regulatory approval has to some extent been
acilitated by the WHO  Prequaliﬁcation of Vaccines Programme
75] which works in cooperation with national regulatory agen-
ies. WHO  prequaliﬁcation led to the licensure of the MenAfriVac
eningococcal A conjugate vaccine in 2010 [76] and the Shancol
nactivated cholera vaccine from Shantha Biotechs Ltd. of India in
011 [77]. Despite these improvements, there is still a need to fur-
her reduce the length of time currently required to approve new
accines for low-income countries.
An additional area where the vaccine development pathway can
e accelerated is through the development of functional in vitro
ssays that can quickly determine whether candidate vaccines
re efﬁcacious in preclinical and clinical studies. Such assays can
ead to reduced reliance on animal models. One of these assays is
he Meningococcal Antigen Typing System (MATS) [78]. Although
eveloped to determine strain coverage of the 4CMenB Meningo-
occal B vaccine, the assay is being adapted for use with new
eningococcal vaccines for the African Meningitis Belt.
.3. Innovation in vaccine delivery
Two clear ways in which delivery of low-income country vac-
ines can be improved is the formulation of heat-stable vaccines
nd vaccines that can be delivered without needles. The develop-
ent of heat-stable vaccines is a major focus of research efforts.
his is because setting up and maintaining cold-chains in countries
ith limited infrastructure and high ambient temperatures adds
onsiderable expense to vaccination programmes [79]. Develop-
ng vaccines that can be delivered without the use of needles is
lso of great interest [80], because of issues related to safe needle
isposal and the possibility of infection with blood borne viruses,
articularly hepatitis B and HIV.
Much consideration is being given to the optimal timing of vac-
ine delivery. This is partly because of concerns about potential
vercrowding of the EPI with possible immunological interference,
nd the suboptimal vaccine responses in infants compared to those
n older age groups. An innovation in this area is vaccination in
regnancy where passive transfer of maternal antibody to the foe-
us during the third trimester protects the child during the neonatal
eriod, when there is a high level of mortality due to infection in
ow-income countries [81]. There is growing evidence indicating
he beneﬁt of vaccination against inﬂuenza during pregnancy in
ow-income countries [82] and in time this approach may  extend
o other vaccines.
.4. Genomics
The genomic revolution has had a major impact on the vaccine
ndustry and will continue to do so. The availability of the ﬁrst
hole genome sequences from pathogens made the reverse vac-
inology approach possible [58,59] (Section 8.1.3). Whole genome
equencing of multiple pathogen isolates has become increasingly
ffordable permitting the analysis of antigenic conservation and
iversity across pathogen populations. This has recently been
pplied to large international collections of isolates of Shigella
onnei [83], Salmonella Typhi [84] and Salmonella Typhimurium
85], all of which are targets of new vaccines for low-incomeunology 25 (2013) 114– 123
countries. The public availability of these genomes is helping the
design of broadly-protective vaccines against these pathogens. On
the host side, a twin study in the Gambia indicated that there is a
major genetic component to the immune response to vaccination
among children in low-income countries [86]. Advances in human
genomics continue to improve our understanding of genetic sus-
ceptibility of populations in low-income, as well as high-income
countries, to infectious diseases [87,88]. These should facilitate
rational vaccine design and help identify which populations
require particular vaccinations most.
9. Partnership
A continuous theme throughout this review is the essential
need for partnership in order to realise the dream of new vac-
cines for low-income countries. There is a need for the institutes
and companies in the developed world who  seek to develop these
new vaccines to establish partnerships with the public, health-care
professionals, scientists, policy makers and potential manufactur-Fig. 3. Global partnerships in development of vaccines for low-income countries.
Successful development of new vaccines for low-income countries will rely on
partnerships between high-income and low-income countries, and among both
high-income countries and low-income countries. These partnerships need to
involve industry, academia and health policy makers in both groups of countries.
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It is essential that the public health need for a vaccine in a low-
ncome country is recognised for that country to use the vaccine.
or diseases with a clear clinical manifestation such as meningi-
is and cholera, this is relatively easy. Where clinical presentation
s non-speciﬁc and can masquerade as another disease, the task is
ess straightforward. This is the case with invasive nontyphoidal
almonella disease (iNTS), the commonest cause of bacteraemia in
ub-Saharan African [89]. Studies have reported an associated case-
atality rate of around 20% [90]. Since the normal presentation of
NTS is with fever alone, it often goes unrecognised and can be
istaken for malaria with which it is frequently associated [91].
artnership with scientists and healthcare workers dealing with
NTS is key to increasing public awareness of this disease.
Public awareness of potentially vaccine-preventable diseases in
ow-income countries requires good epidemiological data. These
re important for health ministries in low-income countries and
lso for global health policy organisations such as WHO. Again, part-
ership with local scientists and healthcare workers is key if the
ecessary studies to collect these data are to take place. Examples
f successful partnerships are the BMGF-sponsored GEMS study
nvestigating the aetiology of diarrhoea in low-income countries
34] and the epidemiological surveys of typhoid incidence in the
eveloping world supported by the Coalition against Typhoid (CaT)
92]. Such studies also provide the opportunity to collect relevant
isease-causing isolates which can be analysed in genome studies
o facilitate appropriate vaccine design.
The mechanisms of pathogenesis and protective immunity for
 number of diseases in low-income countries are poorly under-
tood. This can be further complicated by the high prevalence of
oinfections such as HIV and malaria, and comorbidities such as
alnutrition which impair immunity and can increase suscepti-
ility to vaccine-preventable diseases. Studies of host immunity
n high income countries are often not comparable with those on
opulations in low-income countries, even when healthy individ-
als are studied [93]. Partnership with local research scientists
nvestigating host-pathogen interactions is valuable for improving
nderstanding and facilitating vaccine design. Such partnerships
ith low-income countries are more effective if they involve the
se of existing networks across a number of countries or establish
uch networks if they do not exist. The GEMS and CaT epidemiologi-
al studies have used such networks and a network of 11 sites across
ine countries in sub-Saharan Africa was established for Phase 3
linical trials of the RTS,S/AS01 malaria vaccine [29].
There will be increasing opportunities in the future for
artnership with vaccine manufacturers from low-income and
iddle-income countries. The expansion of vaccine manufacturing
apacity in India and similar countries is set to continue leading
o greater capacity for vaccine production with affordable pri-
ing. Investment in capacity building and partnership in technology
ransfer will help support this expanding manufacturing base.
Finally, partnership and more open interaction between vac-
ine institutes and companies in the developed world will facilitate
imely development of new vaccines for low-income countries.
o some extent, this goes against standard industrial practice
n relation to technical knowledge and expertise. Nevertheless,
he resources committed speciﬁcally to vaccines for low-income
ountries are a fraction of those available for vaccines for markets
n industrialised countries. Consequently, increased cooperation
ithin the industrial sector has great potential to make a difference
o thousands of lives.0. Conclusion
Early in the New Decade of Vaccines is an exciting time to be
nvolved in the development of vaccines for low-income countries.
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Never before have there been the same opportunities to move
ahead with such vaccines. This is shown by the clear role that
vaccines can play in achieving the United Nations’ Millennium
Goals, together with international support coordinated through
the GAVI Alliance and new vaccine institutes with access to
industrial expertise in vaccinology. The successful development of
a conjugate vaccine against meningococcal group A meningitis for
Africa symbolises a paradigm shift in the vaccine industry by new
vaccines being made primarily for low-income countries.
Despite these major achievements, the challenges that remain
are considerable, not least that there are too few resources avail-
able to fully implement programmes using existing vaccines in
low-income countries. This particularly applies to children under
ﬁve years of age. There is a need for the wise use of these
resources including the exploitation of recent innovative tech-
nologies in vaccinology including conjugation technology, reverse
vaccinology, new adjuvants and speciﬁc innovations for low-
income country vaccines such as GMMA  technology. Information
available from the increasing number of pathogen and human
genomes needs to be incorporated into the process of vaccine
development. Careful consideration must be given to the tim-
ing of vaccination with the problems of a crowded EPI schedule
and suboptimal immune responses in infancy. This needs to be
combined with a keen awareness of the public health needs of
low-income countries and information from well-designed epi-
demiological studies.
Key to all of this is close partnership with researchers and
leaders in low-income countries from the earliest stages of the
development of a new vaccine. This involves interactions at mul-
tiple levels, including interactions with researchers to better
understand the diseases for which vaccines are being developed,
discussions with health policy makers concerning the need for
new vaccines and the involvement of the increasing number of
vaccine manufacturing facilities which are well placed to produce
vaccines at affordable prices. Finally, increased openness and part-
nership within the vaccine industry itself could make a major
difference to the success of these new vaccines over the next 10
years.
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